Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 3056-3063

  Li, Zengshan ^a,b   Carrier, Latonya ^a   Rowan, Brian G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CASPASE; CASPASE 8; CASPASE 9; METHYLSELENINIC ACID; ORGANOSELENIUM DERIVATIVE; SELENIUM; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CYTOCHROMES C; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; G1 PHASE; HUMANS; MEMBRANE PROTEINS; MITOCHONDRIA; MODELS, BIOLOGICAL; ORGANOSELENIUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS; TAMOXIFEN;

EID: 54049142528     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2142     Document Type: Article

References (43)

1. Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer 1999;35:1963-73.
2. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999;35:1974-85.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
4. Johnston SR, Dowsett M, Smith IE. Towards a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol 1992;3:503-11.
5. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
6. Clark LC, Combs GF, Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
7. Gerhardsson L, Brune D, Nordberg IG, Wester PO. Protective effect of selenium on lung cancer in smelter workers. Br J Ind Med 1985;42:617-26.
8. Glattre E, Thomassen Y, Thoresen SO, et al. Prediagnostic serum selenium in a case-control study of thyroid cancer. Int J Epidemiol 1989;18:45-9.
9. Hardell L, Degerman A, Tomic R, Marklund SL, Bergfors M. Levels of selenium in plasma and glutathione peroxidase in erythrocytes in patients with prostate cancer or benign hyperplasia. Eur J Cancer Prev 1995;4:91-5.
10. Jaskiewicz K, Marasas WF, Rossouw JE, Van Niekerk FE, Heine Tech EW. Selenium and other mineral elements in populations at risk for esophageal cancer. Cancer 1988;62:2635-9.
11. Kawamori T, El Bayoumy K, Ji BY, Rodriguez JG, Rao CV, Reddy BS. Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis. Int J Oncol 1998;13:29-34.
12. Last KW, Cornelius V, Delves T, et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:2335-41.
13. Miyamoto H, Araya Y, Ito M, et al. Serum selenium and vitamin E concentrations in families of lung cancer patients. Cancer 1987;60:1159-62.
14. Reinhold U, Biltz H, Bayer W, Schmidt KH. Serum selenium levels in patients with malignant melanoma. Acta Derm Venereol 1989;69:132-6.
15. Westin T, Ahlbom E, Johansson E, Sandstrom B, Karlberg I, Edstrom S. Circulating levels of selenium and zinc in relation to nutritional status in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1989;115:1079-82.
16. Nelson MA, Porterfield BW, Jacobs ET, Clark LC. Selenium and prostate cancer prevention. Semin Urol Oncol 1999;17:91-6.
17. Marshall JR. Larry Clark's legacy: randomized controlled, selenium-based prostate cancer chemoprevention trials. Nutr Cancer 2001;40:74-7.
18. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60:2882-6.
19. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004;10:2561-9.
20. Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C. Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 2007;6:1031-8.
21. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001;61:3062-70.
22. Danova M, Pellicciari C, Zibera C, et al. Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression. Ann N Y Acad Sci 1993;698:174-81.
23. 1 phase. Cancer Res 1983;43:3583-5.
24. Brunner N, Frandsen TL, Holst-Hansen C, et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 1993;53:3229-32.
25. Shah YM, Al Dhaheri M, Dong Y, Ip C, Jones FE, Rowan BG. Selenium disrupts estrogen receptor (α) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Mol Cancer Ther 2005;4:1239-49.
26. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res 2006;66:4309-18.
27. Montaner B, Perez-Tomas R. Prodigiosin induces caspase-9 and caspase-8 activation and cytochrome c release in Jurkat T cells. Ann NY Acad Sci 2002;973:246-9.
28. Zu K, Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 2003;63:6988-95.
29. Waring P, Mullbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 1999;77:312-7.
30. Kojima H, Endo K, Moriyama H, et al. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem 1998;273:16647-50.
31. Yamaguchi K, Uzzo RG, Pimkina J, et al. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 2005;24:5868-77.
32. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21.
33. Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA, Gruss P. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 1998;94:727-37.
34. Kuida K. Caspase-9. Int J Biochem Cell Biol 2000;32:121-4.
35. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
36. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357-60.
37. McDonnell MA, Wang D, Khan SM, Vander Heiden MG, Kelekar A. Caspase-9 is activated in a cytochrome c-independent manner early during TNFa-induced apoptosis in murine cells. Cell Death Differ 2003;10:1005-15.
38. Gaddy DF, Lyles DS. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 2005;79:4170-9.
39. Rosenthal DS, Velena A, Chou FP, et al. Expression of dominant-negative Fas-associated death domain blocks human keratinocyte apoptosis and vesication induced by sulfur mustard. J Biol Chem 2003;278:8531-40.
40. Pan J, Xu G, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab 2001;86:4731-40.
41. Ravi R, Bedi A. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res 2002;62:4180-5.
42. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-30.
43. Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 2002;277:45695-703.